J Gynecol Oncol | Volume 3, Issue 4 | Research Article | Open Access
Sarah B5, Aymeric M5, Pandora J5, Postec-Ollitrault E5, Sylvain R3, Tanniou J3, Adissa T1, Talagas M4, Bommelaere F3, Collet M6,3, Merviel P5 and Payan C1,2*
1Department of Microbiology, Hospital Center Regional University Morvan De Brest, France
2Department of Medicine and Health Sciences, Brest-UBL University, France
3Hospital Center Regional University Morvan De Brest, France
4Laboratory of Cytology-Anatomy-Pathology, Hospital Center Regional University Morvan De Brest, France
5Department of Gynecology and Obstetrics, Centre Hospitalier Regional Universitaire, France
6Department of Gynecology and Obstetrics, Landerneau Hospital, France
*Correspondance to: Christopher Payan
Fulltext PDFThe poor coverage of Cervical Cancer (CC) screening in France and the insufficient performance of the cervical smear test prompt a review of screening strategies. The main objective of the PAPUAPV study is to compare two alternative approaches to CC screening, the Human papillomavirus (HPV) testing on self-collected First-Void Urine (FVU) and Self-Collected Vaginal (SCV) samples. The secondary objectives were to evaluate the women’s preference, to assess the feasibility of selfsampling, and to determine their sensitivity and specificity to detect high-grade lesions. From April 2014 to October 2015, 461 patients were included: 176 patients from gynecological consultations (group 1) and 285 patients from the general population (group 2). Each of them performed both urinary and vaginal self-sampling. The samples were analyzed by real-time PCR and genotyping. A satisfaction questionnaire was completed to determine the best strategy to adopt between these self-sampling methods. Cervical smear test results were then collected. The prevalence of oncogenic HPV in our population was 18%, comparable in both groups. The concordance between samples was moderate (kappa coefficient k=0.50) but there was no significant difference between vaginal and urinary samples for HR HPV detection rate (14.1% and 11.5%, p=0.45). Urinary self-sampling was preferred over vaginal self-sampling (40.5% and 13.3%, respectively, p<0.001). Sensitivity and specificity to detect high-grade lesions were not significantly different between vaginal and urinary self-sampling (respectively 100% vs. 100% p=1 and 67.5% vs. 63.2% p=0.64). The lack of difference between vaginal and urinary self-sampling in terms of diagnostic performance places them both as alternatives to cervical smear tests in the screening for cervical cancer, as recommended in France by the 2014 to 2019 Cancer program.
Human papillomavirus; Screening; Self-sampling: CC; SCV
Sarah B, Aymeric M, Pandora J, Postec-Ollitrault E, Sylvain R, Tanniou J, et al. Urinary or Vaginal Self- Sampling for Human papillomavirus Testing in Organized Cervical Cancer Screening. J Gynecol Oncol. 2020; 3(4): 1041.